Clinical Trials Directory

Trials / Unknown

UnknownNCT04108494

A Trial of Total Versus Partial Omentectomy for Advanced Gastric Cancer in Gastrectomy

A Single-center, Randomized, Controlled Trial to Evaluate Total Versus Partial Omentectomy for Advanced Gastric Cancer in Radical Gastrectomy

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
418 (estimated)
Sponsor
Tianjin Medical University Cancer Institute and Hospital · Academic / Other
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

The main purpose of this study is to evaluate the impact of omentectomy for advanced gastric cancer on patient survival.

Detailed description

Surgical resection is the mainstay of treatment for gastric cancer. The extent of surgical resection includes total or subtotal gastrectomy, D2 lymphadenectomy, and prophylactic or therapeutic resection of the surrounding organs or tissues (e.g., omentum, peritoneum, etc). However, the oncologic importance of omentectomy during gastrectomy remains unclear. The European guidelines do not give any advice regarding omentectomy, whereas the most recent American guidelines advise to resect both the greater and lesser omentum. Alternatively, the Japanese gastric cancer treatment guidelines recommends preservation of the greater omentum at \>3 cm from the gastroepiploic arcade for patients with T1-T2 tumors and total omentectomy for patients with T3-T4 tumors. In order to evaluate the impact of omentectomy for advanced gastric cancer on patient survival, we designed this trial. Patients who received curative gastrectomy were divided into two groups based on whether they underwent omentectomy. The primary endpoint is the 3-year relapse-free survival rate and the secondary endpoints are 5-year overall survival, and postoperative morbidity.

Conditions

Interventions

TypeNameDescription
PROCEDUREType of omentectomyPartial omentectomy with preservation of the greater omentum at \>3 cm from the gastroepiploic arcade.Control group with total omentectomy.

Timeline

Start date
2019-01-01
Primary completion
2020-12-31
Completion
2025-12-31
First posted
2019-09-30
Last updated
2019-09-30

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT04108494. Inclusion in this directory is not an endorsement.